Phaseline

Companies › NovaRock Biotherapeutics

NovaRock Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NBL-020 for Injection–Phase 1Advanced Malignant TumorsDec 2026
NBL-028
anti-CLDN6 antibody-drug conjugate
CLDN6Phase 1Advanced Solid TumorJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05877924NBL-020 for InjectionPhase 1Advanced Malignant TumorsOncologyDec 2026
NCT06223256NBL-028Phase 1Advanced Solid TumorOncologyJan 2027

Targets

CLDN6 (1)

Companies with the same targets

BioNTech Cell & Gene Therapies Context Therapeutics BeOne Medicines

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.